FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Naohito Shirai

Research Profile

Living Beings

Helicobacter pylori

Chemicals & Drugs

Disorders

Helicobacter Infections

Physiology

Genotype

Procedures

Anatomy

Gastric Mucosa

Geographic Areas

Japan

Co-author Network

Publications

TOP 3
Takahisa Furuta; Hitomi Ichikawa; Chise Kodaira; Masafumi Nishino; Satoshi Osawa; Shu Sahara; Ken Sugimoto; Mitsushige Sugimoto; Takahiro Uotani; Takanori Yamada; Mihoko Yamade; Naohito Shirai
[Judgment of eradication of H. pylori based on percent changes in serum pepsinogens].
Mitsushige Sugimoto; T Uotani; Mihoko Yamade; H Ichikawa; Chise Kodaira; Hiroaki Miyajima; Masafumi Nishino; S Sahara; Naohito Shirai; K Sugimoto; Takahisa Furuta
Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype.
Takahisa Furuta; Mitsushige Sugimoto; Naohito Shirai
Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Naohito Shirai (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Takahisa Furuta; Hitomi Ichikawa; Chise Kodaira; Masafumi Nishino; Satoshi Osawa; Shu Sahara; Ken Sugimoto; Mitsushige Sugimoto; Takahiro Uotani; Takanori Yamada; Mihoko Yamade; Naohito Shirai
[Judgment of eradication of H. pylori based on percent changes in serum pepsinogens].
Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 2013;110(2):210-7.
2012: Mitsushige Sugimoto; T Uotani; Mihoko Yamade; H Ichikawa; Chise Kodaira; Hiroaki Miyajima; Masafumi Nishino; S Sahara; Naohito Shirai; K Sugimoto; Takahisa Furuta
Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype.
Alimentary pharmacology & therapeutics 2012;36(7):627-34.
2012: Takahisa Furuta; Mitsushige Sugimoto; Naohito Shirai
Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19.
Molecular diagnosis & therapy 2012;16(4):223-34.
2012: Mitsushige Sugimoto; Yoshio Yamaoka; Naohito Shirai; Takahisa Furuta
Role of renin-angiotensin system in gastric oncogenesis.
Journal of gastroenterology and hepatology 2012;27(3):442-51.
2011: Masafumi Nishino; Naohito Shirai; Mitsushige Sugimoto; Haruhiko Sugimura; Tatsuo Tanaka; Takahiro Uotani; Mihoko Yamade; Akira Hishida; Mutsuhiro Ikuma; Chise Kodaira; Takahisa Furuta
Preventive effects of lansoprazole and famotidine on gastric mucosal injury induced by low-dose aspirin in Helicobacter pylori-negative healthy volunteers.
Journal of clinical pharmacology 2011;51(7):1079-86.
2010: Takahisa Furuta; Mitsushige Sugimoto; Chise Kodaira; Masafumi Nishino; Mihoko Yamade; Takahiro Uotani; Mutsuhiro Ikuma; Naohito Shirai
The dual therapy with 4 times daily dosing of rabeprazole and amoxicillin as the 3rd rescue regimen for eradication of H. pylori.
Hepato-gastroenterology 2010;57(102-103):1314-9.
2010: Masafumi Nishino; Mitsushige Sugimoto; Chise Kodaira; Mihoko Yamade; Naohito Shirai; Mutsuhiro Ikuma; Tatsuo Tanaka; Haruhiko Sugimura; Akira Hishida; Takahisa Furuta
Relationship between low-dose aspirin-induced gastric mucosal injury and intragastric pH in healthy volunteers.
Digestive diseases and sciences 2010;55(6):1627-36.
2009: Takahisa Furuta; Mitsushige Sugimoto; Chise Kodaira; Masafumi Nishino; Mihoko Yamade; Mutsuhiro Ikuma; Naohito Shirai; Hiroshi Watanabe; Kazuo Umemura; Michio Kimura; Akira Hishida
CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole.
European journal of clinical pharmacology 2009;65(7):693-8.
2009: Chise Kodaira; Mitsushige Sugimoto; Masafumi Nishino; Mihoko Yamade; Naohito Shirai; Shinya Uchida; Mutsuhiro Ikuma; Shizuo Yamada; Hiroshi Watanabe; Akira Hishida; Takahisa Furuta
Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects.
European journal of clinical pharmacology 2009;65(6):593-600.
2008: Mitsushige Sugimoto; Takahisa Furuta; Akiko Nakamura; Naohito Shirai; Mutsuhiro Ikuma; Shingen Misaka; Shinya Uchida; Hiroshi Watanabe; Kyoichi Ohashi; Takashi Ishizaki; Akira Hishida
Maintenance time of sedative effects after an intravenous infusion of diazepam: a guide for endoscopy using diazepam.
World journal of gastroenterology : WJG 2008;14(33):5197-203.
2008: Mitsushige Sugimoto; Takahisa Furuta; Naohito Shirai; Chise Kodaira; Masafumi Nishino; Mihoko Yamade; Mutsuhiro Ikuma; Haruhiko Sugimura; Takashi Ishizaki; Akira Hishida
MDR1 C3435T polymorphism has no influence on developing Helicobacter pylori infection-related gastric cancer and peptic ulcer in Japanese.
Life sciences 2008;83(7-8):301-4.
2008: Naohito Shirai; Takahisa Furuta; Mitsushige Sugimoto; Shigeru Kanaoka; Fumitoshi Watanabe; Misako Takashima; Masami Yamada; Hajime Futami; Yoshihiko Sato; Hiroyuki Kubota; Makoto Kodaira; Masayoshi Kajimura; Masato Maekawa; Akira Hishida
Serum pepsinogens as an early diagnostic marker of H. pylori eradication.
Hepato-gastroenterology 2008;55(82-83):486-90.
2007: Mitsushige Sugimoto; Takahisa Furuta; Naohito Shirai; Chise Kodaira; Masafumi Nishino; Mihoko Yamade; Mutsuhiro Ikuma; Hiroshi Watanabe; Kyoichi Ohashi; Akira Hishida; Takashi Ishizaki
Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics.
Expert opinion on pharmacotherapy 2007;8(16):2701-17.
2007: Takahisa Furuta; Yoshihiro Soya; Mitsushige Sugimoto; Naohito Shirai; Akiko Nakamura; Chise Kodaira; Masafumi Nishino; Masumi Okuda; Tadayoshi Okimoto; Kazunari Murakami; Toshio Fujioka; Akira Hishida
Modified allele-specific primer-polymerase chain reaction method for analysis of susceptibility of Helicobacter pylori strains to clarithromycin.
Journal of gastroenterology and hepatology 2007;22(11):1810-5.
2007: Takahisa Furuta; Mitsushige Sugimoto; Naohito Shirai; Takashi Ishizaki
CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.
Pharmacogenomics 2007;8(9):1199-210.
2007: Mitsushige Sugimoto; Takahisa Furuta; Naohito Shirai; Akiko Nakamura; Masayoshi Kajimura; Haruhiko Sugimura; Akira Hishida
Effects of interleukin-10 gene polymorphism on the development of gastric cancer and peptic ulcer in Japanese subjects.
Journal of gastroenterology and hepatology 2007;22(9):1443-9.
2007: Takahisa Furuta; Mitsushige Sugimoto; Naohito Shirai; F Matsushita; H Nakajima; J Kumagai; K Senoo; Chise Kodaira; Masafumi Nishino; Mihoko Yamade; Mutsuhiro Ikuma; Hiroshi Watanabe; K Umemura; Takashi Ishizaki; Akira Hishida
Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori.
Alimentary pharmacology & therapeutics 2007;26(5):693-703.
2007: Mitsushige Sugimoto; Takahisa Furuta; Naohito Shirai; Chise Kodaira; Masafumi Nishino; Mutsuhiro Ikuma; Haruhiko Sugimura; Akira Hishida
Role of angiotensinogen gene polymorphism on Helicobacter pylori infection-related gastric cancer risk in Japanese.
Carcinogenesis 2007;28(9):2036-40.
2007: Mitsushige Sugimoto; Takahisa Furuta; Naohito Shirai; Chise Kodaira; Masafumi Nishino; Mutsuhiro Ikuma; Takashi Ishizaki; Akira Hishida
Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy.
Helicobacter 2007;12(4):317-23.
2007: Naohito Shirai; Mitsushige Sugimoto; Chise Kodaira; Masafumi Nishino; Mutsuhiro Ikuma; Masayoshi Kajimura; Kyoichi Ohashi; Takashi Ishizaki; Akira Hishida; Takahisa Furuta
Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy.
European journal of clinical pharmacology 2007;63(8):743-9.
2007: Akiko Nakamura; Takahisa Furuta; Naohito Shirai; Mitsushige Sugimoto; Masayoshi Kajimura; Yoshihiro Soya; Akira Hishida
Determination of mutations of the 23S rRNA gene of Helicobacter pylori by allele specific primer-polymerase chain reaction method.
Journal of gastroenterology and hepatology 2007;22(7):1057-63.
2007: Takahisa Furuta; Naohito Shirai; Makoto Kodaira; Mitsushige Sugimoto; Atsuhiro Nogaki; S Kuriyama; M Iwaizumi; Mihoko Yamade; I Terakawa; Kyoichi Ohashi; Takashi Ishizaki; Akira Hishida
Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori.
Clinical pharmacology and therapeutics 2007;81(4):521-8.
2007: Mitsushige Sugimoto; Takahisa Furuta; Naohito Shirai; Akiko Nakamura; Fang Xiao; Masayoshi Kajimura; Haruhiko Sugimura; Akira Hishida
Different effects of polymorphisms of tumor necrosis factor-alpha and interleukin-1 beta on development of peptic ulcer and gastric cancer.
Journal of gastroenterology and hepatology 2007;22(1):51-9.
2006: Mitsushige Sugimoto; Takahisa Furuta; Naohito Shirai; Mutsuhiro Ikuma; Akira Hishida; Takashi Ishizaki
Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status.
Clinical pharmacology and therapeutics 2006;80(5):539-48.
2006: Mitsushige Sugimoto; Takahisa Furuta; Naohito Shirai; Mutsuhiro Ikuma; Haruhiko Sugimura; Akira Hishida
Influences of chymase and angiotensin I-converting enzyme gene polymorphisms on gastric cancer risks in Japan.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2006;15(10):1929-34.
2006: Mitsushige Sugimoto; Takahisa Furuta; Naohito Shirai; Mutsuhiro Ikuma; Akira Hishida; Takashi Ishizaki
Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy.
Clinical pharmacology and therapeutics 2006;80(1):41-50.
2006: Mitsushige Sugimoto; Masayoshi Kajimura; Naohito Shirai; Takahisa Furuta; Shigeru Kanaoka; Mutsuhiro Ikuma; Yoshihiko Sato; Akira Hishida
Outcome of radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma refractory to Helicobacter pylori eradication therapy.
Internal medicine (Tokyo, Japan) 2006;45(6):405-9.
2005: Akihiro Takeshita; Kaori Shinjo; Kensuke Naito; Hirotaka Matsui; Naohi Sahara; Kazuyuki Shigeno; Taeko Suzumura; Toshinobu Horii; Naohito Shirai; Masato Maekawa; Yoshihiro Yada; Hirofumi Teshima; Jin Takeuchi; Kazunori Ohnishi; Ryuzo Ohno
Two patients with all-trans retinoic acid-resistant acute promyelocytic leukemia treated successfully with gemtuzumab ozogamicin as a single agent.
International journal of hematology 2005;82(5):445-8.
2005: Mitsushige Sugimoto; Takahisa Furuta; Naohito Shirai; Akiko Nakamura; Masayoshi Kajimura; H Sugimura; Akira Hishida; Takashi Ishizaki
Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection.
Alimentary pharmacology & therapeutics 2005;22(10):1033-40.
2005: Naohito Shirai; Takahisa Furuta; Mitsushige Sugimoto; Akiko Nakamura
[High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy].
Nihon rinsho. Japanese journal of clinical medicine 2005;63 Suppl 11():438-41.
2005: Takahisa Furuta; Mitsushige Sugimoto; Akiko Nakamura; Naohito Shirai
[Susceptibility to antibiotics and drug metabolism in patients with H. pylori infection refractory to the initial treatment--therapeutic strategy based on susceptibility to CAM and CYP2C19 polymorphism].
Nihon rinsho. Japanese journal of clinical medicine 2005;63 Suppl 11():426-33.
2005: Mitsushige Sugimoto; Takahisa Furuta; Akiko Nakmura; Naohito Shirai
[Recent topics on important drugs for H. pylori eradication: Rabeprazole].
Nihon rinsho. Japanese journal of clinical medicine 2005;63 Suppl 11():350-3.
2005: Akihiro Takeshita; Kaori Shinjo; Kensuke Naito; Hirotaka Matsui; Naohi Sahara; Kazuyuki Shigeno; Toshinobu Horii; Naohito Shirai; Masato Maekawa; Kazunori Ohnishi; Tomoki Naoe; Ryuzo Ohno
Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells.
Leukemia 2005;19(8):1306-11.
2005: Takahisa Furuta; Naohito Shirai; Mitsushige Sugimoto; Akiko Nakamura; K Okudaira; Masayoshi Kajimura; Akira Hishida
Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status.
Alimentary pharmacology & therapeutics 2005;22(1):67-74.
2005: Takahisa Furuta; Naohito Shirai; Mitsushige Sugimoto; Akiko Nakamura; Akira Hishida; Takashi Ishizaki
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Drug metabolism and pharmacokinetics 2005;20(3):153-67.
2005: Takahisa Furuta; Yukiko Sagehashi; Naohito Shirai; Mitsushige Sugimoto; Akiko Nakamura; Makoto Kodaira; Kazumi Kenmotsu; Makoto Nagano; Tohru Egashira; Koji Ueda; Masao Yoneyama; Kyoichi Ohashi; Takashi Ishizaki; Akira Hishida
Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2005;3(6):564-73.
2005: Mitsushige Sugimoto; Takahisa Furuta; Naohito Shirai; Akiko Nakamura; Masayoshi Kajimura; Akira Hishida; Kyoichi Ohashi; Takashi Ishizaki
Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes.
Clinical pharmacology and therapeutics 2005;77(4):302-11.
2004: Mitsushige Sugimoto; Takahisa Furuta; Naohito Shirai; Masayoshi Kajimura; Akira Hishida; Masaharu Sakurai; Kyoichi Ohashi; Takashi Ishizaki
Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
Clinical pharmacology and therapeutics 2004;76(4):290-301.
2004: Masato Maekawa; Tomonori Nagaoka; Terumi Taniguchi; Hitomi Higashi; Haruhiko Sugimura; Kokichi Sugano; Hiroyuki Yonekawa; Takatomo Satoh; Toshinobu Horii; Naohito Shirai; Akihiro Takeshita; Takashi Kanno
Three-dimensional microarray compared with PCR-single-strand conformation polymorphism analysis/DNA sequencing for mutation analysis of K-ras codons 12 and 13.
Clinical chemistry 2004;50(8):1322-7.
2004: Takahisa Furuta; Naohito Shirai; Mitsushige Sugimoto; Kyoichi Ohashi; Takashi Ishizaki
Pharmacogenomics of proton pump inhibitors.
Pharmacogenomics 2004;5(2):181-202.
2004: Takahisa Furuta; Naohito Shirai; Fang Xiao; Emad M El-Omar; Charles S Rabkin; Haruhiko Sugimura; Takashi Ishizaki; Kyoichi Ohashi
Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2004;2(1):22-30.
2003: Takahisa Furuta; Naohito Shirai; Fang Xiao; Misako Takashita; Mitsushige Sugimoto; Masayoshi Kajimura; Kyoichi Ohashi; Takashi Ishizaki
High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.
Hepato-gastroenterology 2003;50(54):2274-8.
2003: Hiroyuki Hanai; Koutarou Tozawa; Ken Takeuchi; Takayuki Iida; Hajime Arai; Shigeru Kanaoka; Ken Sugimoto; Kennichi Yoshida; Teruhiko Iwasaki; Akiko Nakamura; Yoshisuke Hosoda; Naohito Shirai; Kouki Hirasawa; Kenichiro Takahira; Hideki Kataoka; Munetaka Sano; Megumi Osawa; Shigemitsu Sugimoto
[Clinical significance of faecal calprotectin levels in patients with ulcerative colitis].
Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 2003;100(1):21-7.
2002: Takahisa Furuta; Naohito Shirai; Fumitoshi Watanabe; Satoru Honda; Ken Takeuchi; Takayuki Iida; Yoshihiko Sato; Masayoshi Kajimura; Hajime Futami; Shigekazu Takayanagi; Masami Yamada; Kyoichi Ohashi; Takashi Ishizaki; Hiroyuki Hanai
Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole.
Clinical pharmacology and therapeutics 2002;72(4):453-60.
2002: Takahisa Furuta; Emad M El-Omar; Fang Xiao; Naohito Shirai; Misako Takashima; Haruhiko Sugimura; Haruhiko Sugimurra
Interleukin 1beta polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan.
Gastroenterology 2002;123(1):92-105.
2002: Naohito Shirai; Takahisa Furuta; Fang Xiao; Masayoshi Kajimura; Hiroyuki Hanai; Kyoichi Ohashi; Takashi Ishizaki
Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups.
Alimentary pharmacology & therapeutics 2002;16(4):837-46.
2002: Takahisa Furuta; Naohito Shirai; Fang Xiao; Misako Takashima; Hiroyuki Hanai
Effect of Helicobacter pylori infection and its eradication on nutrition.
Alimentary pharmacology & therapeutics 2002;16(4):799-806.
2002: Naohito Shirai; Takahisa Furuta
[High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy: CYP2C19 polymorphism].
Nihon rinsho. Japanese journal of clinical medicine 2002;60 Suppl 2():439-44.
2002: Takahisa Furuta; Naohito Shirai; Misako Takashima; Fang Xiao; Haruhiko Sugimura
Effect of genotypic differences in interleukin-1 beta on gastric acid secretion in Japanese patients infected with Helicobacter pylori.
The American journal of medicine 2002;112(2):141-3.
2001: Naohito Shirai; Takahisa Furuta; Y Moriyama; H Okochi; K Kobayashi; Misako Takashima; Fang Xiao; Kazuhiro Kosuge; K Nakagawa; Hiroyuki Hanai; K Chiba; Kyoichi Ohashi; Takashi Ishizaki
Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.
Alimentary pharmacology & therapeutics 2001;15(12):1929-37.
2001: Takahisa Furuta; Naohito Shirai; Fang Xiao; Kyoichi Ohashi; Takashi Ishizaki
Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
Clinical pharmacology and therapeutics 2001;70(5):484-92.
2001: Takahisa Furuta; Naohito Shirai; Misako Takashima; Fang Xiao; Hiroyuki Hanai; K Nakagawa; Haruhiko Sugimura; Kyoichi Ohashi; Takashi Ishizaki
Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin.
Pharmacogenetics 2001;11(4):341-8.
2001: Fang Xiao; Takahisa Furuta; Misako Takashima; Naohito Shirai; Hiroyuki Hanai
Effects of cyclooxygenase-2 inhibitor on gastric acid secretion in Helicobacter pylori-infected C57BL/6 mice.
Scandinavian journal of gastroenterology 2001;36(6):577-83.
2001: Fang Xiao; Takahisa Furuta; Misako Takashima; Naohito Shirai; Hiroyuki Hanai
Involvement of cyclooxygenase-2 in hyperplastic gastritis induced by Helicobacter pylori infection in C57BL/6 mice.
Alimentary pharmacology & therapeutics 2001;15(6):875-86.
2001: Takahisa Furuta; Naohito Shirai; Misako Takashima; Fang Xiao; Hiroyuki Hanai; Haruhiko Sugimura; Kyoichi Ohashi; Takashi Ishizaki; Eizo Kaneko
Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
Clinical pharmacology and therapeutics 2001;69(3):158-68.
2000: Takahisa Furuta; Misako Takashima; Naohito Shirai; Fang Xiao; Hiroyuki Hanai; Kyoichi Ohashi; Takashi Ishizaki
Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient.
Clinical pharmacology and therapeutics 2000;67(6):684-9.
2000: Naohito Shirai; Hiroyuki Hanai; Masayoshi Kajimura; Hideki Kataoka; Kennichi Yoshida; Masanori Nakagawara; M Nemoto; M Nagasawa; E Kaneko
Successful treatment of percutaneous transhepatic papillary dilation in patients with obstructive jaundice due to common bile duct stones after Billroth II gastrectomy: report of two emergent cases.
Journal of clinical gastroenterology 2000;30(1):91-3.
1999: Takahisa Furuta; Kyoichi Ohashi; K Kobayashi; I Iida; H Yoshida; Naohito Shirai; Misako Takashima; Kazuhiro Kosuge; Hiroyuki Hanai; K Chiba; Takashi Ishizaki; Eizo Kaneko
Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans.
Clinical pharmacology and therapeutics 1999;66(3):265-74.
1999: Takahisa Furuta; S Baba; Misako Takashima; Naohito Shirai; Fang Xiao; Hajime Futami; H Arai; Hiroyuki Hanai; Eizo Kaneko
H+/K+-adenosine triphosphatase mRNA in gastric fundic gland mucosa in patients infected with Helicobacter pylori.
Scandinavian journal of gastroenterology 1999;34(4):384-90.
1999: K Hirano; Hideki Kataoka; M Nagasawa; Masanori Nakagawara; M Nemoto; Naohito Shirai; Kennichi Yoshida; M Kawamura; N Kubo; M Sugimoto; Masayoshi Kajimura
[A case of non-functioning malignant islet cell tumor with egg-shaped calcification].
Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 1999;96(2):189-93.
1999: M Wang; Takahisa Furuta; Misako Takashima; Hajime Futami; Naohito Shirai; Hiroyuki Hanai; Eizo Kaneko
Relation between interleukin-1beta messenger RNA in gastric fundic mucosa and gastric juice pH in patients infected with Helicobacter pylori.
Journal of gastroenterology 1999;34 Suppl 11():10-7.
1997: Masanori Nakagawara; Masayoshi Kajimura; Kennichi Yoshida; Hideki Kataoka; Naohito Shirai; M Ohtake; M Nemoto; M Nagasawa
[Successful treatment of pancreatic pseudocyst with octreotide; a case report].
Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 1997;94(10):712-7.